Ryvu Therapeutics

Please note: The information displayed on this page might be outdated.
Ryvu Therapeutics : Developer of targeted oncology therapies hematology/solid tumors. RVU120 is wholly-owned first-in-class oral CDK8/19 inhibitor in Phase I for AML/MDS with start-up of Phase Ib in solid tumors expected 3Q 2021. Company has small molecule, synthetic lethality platform in pre-clinical development including novel targets WRN and PRMT5. Ryvu's PIM/FLT3 kinase inhibitor in Phase 1/2 is partnered with Menarini.
Based in...
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Biotechnology, Pharmaceuticals
Investment Strategy
Under the Radar
Therapeutic Modalities
Gene Therapy, Small Molecule
2 Sternbacha Street
Kraków, 30-394

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

  • Vatnak Vat-Ho, Chief Business Officer

Top 10 Holders of Ryvu Therapeutics SA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nationale-Nederlanden PTE SA 9.65 1,771,000 0.00 Stakes 5/17/22
PTE PZU SA 9.64 2,227,905 0.00 Funds 12/30/22
Norges Bank Investment Management 7.90 1,827,400 0.00 Funds 12/31/22
Allianz Polska TFI SA 7.31 1,689,419 0.00 Stakes 1/18/23
Allianz Polska PTE SA 6.63 1,532,540 0.00 Stakes 12/30/22
FORUM TFI SA 6.17 1,132,713 0.00 Stakes 5/17/22
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SA 0.00 0 0.00 Stakes 12/30/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.